Henry Jacob Conter

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

Howard West, Michael McCleod, Maen Hussein et al. · The Lancet Oncology · 2019 · 1.7K citations

Medicine, Oncology, Pharmacology +12

Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial

Robert M. Jotte, Federico Cappuzzo, Ihor Vynnychenko et al. · Journal of Thoracic Oncology · 2020 · 607 citations · Full text

Medicine, Oncology, Pharmacology +16

IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.

Robert M. Jotte, Federico Cappuzzo, Ihor Vynnychenko et al. · Journal of Clinical Oncology · 2018 · 220 citations

Medicine, Oncology, Pharmacology +15

Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study

Evan Y. Yu, Michael Kolinsky, William L. Berry et al. · European Urology · 2022 · 79 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC

Federico Cappuzzo, Michael McCleod, Maen Hussein et al. · Annals of Oncology · 2018 · 58 citations · Full text

Medicine, Oncology, Pharmacology +12